Vertex’s alternative to opioids is “not a game-changer,” an analyst said Tuesday as VRTX stock slipped on the company’s Phase 3 test results.

The post Vertex Skids — Its Alternative To Opioids Is ‘Not A Game-Changer,’ Says Analyst appeared first on Investor’s Business Daily.